Branded Direct-to-Consumer Advertising Likely to Provide a Bump in Patient Requests for Sanofi/Regeneron’s Dupixent, but Insurance Coverage and…
Branded Direct-to-Consumer Advertising Likely to Provide a Bump in Patient Requests for
By a
Lack of insurance coverage continues to be the most commonly cited barrier to use, while out-of-pocket costs have become a growing concern amongst dermatologists. Those with ample experience with the brand (i.e., have prescribed to more than ten patients) report that out-of-pocket costs are significantly more of a barrier than those considered "low" users or those yet to prescribe Dupixent. Furthermore, while persistency rates are still very favorable for Dupixent, more than half of patients who have discontinued the agent did so due to insurance reasons or out-of-pocket costs, while an additional 20% were discontinued due to lack of efficacy.
Keywords for this news article include: Pharmaceutical Companies, Advertising, Dermatology, Atopic Dermatitis, Health and Medicine, Spherix Global Insights, Skin Diseases and Conditions, Skin and Connective Tissue Diseases and Conditions.
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2018, NewsRx LLC
KC police investigate evidence storage building fire, uncertain of effect on cases
Study Results from Ajou University School of Medicine Update Understanding of Clinical Trials and Studies (Development and Validation of the Korean…
Advisor News
Annuity News
Health/Employee Benefits News
Life Insurance News